We are live on ! Find out more
BLRX

BioLineRX
BLRX

13 hedge funds and large institutions have $3.69M invested in BioLineRX in 2020 Q1 according to their latest regulatory filings, with 3 funds opening new positions, 2 increasing their positions, 2 reducing their positions, and 1 closing their positions.

New
Increased
Maintained
Reduced
Closed

200% more first-time investments, than exits

New positions opened: 3 | Existing positions closed: 1

8% more funds holding

Funds holding: 12 → 13 (+1)

0% less ownership

Funds ownership: 0.04% → 0.04% (-0%)

0% more repeat investments, than reductions

Existing positions increased: 2 | Existing positions reduced: 2

40% less capital invested

Capital invested by funds: $6.14M → $3.69M (-$2.46M)

Holders
13
Holders Change
+1
Holders Change %
+8.33%
% of All Funds
0.29%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
3
Increased
2
Reduced
2
Closed
1
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Morgan Stanley
Morgan Stanley
New York
+$174K
2
Jane Street
Jane Street
New York
+$103K
3
LPL Financial
LPL Financial
California
+$21.6K
4
CCB
Cutter & Co Brokerage
Missouri
+$3.96K

Top Sellers

Rank Fund Capital Flow
1
SM
Senvest Management
New York
-$208K
2
CAN
Cetera Advisor Networks
California
-$23K
3
NFG
Next Financial Group
Texas
-$1.58K

BLRX Hedge Fund Activity: Q1 2020 in Review

13 of the 4,547 institutional investors tracked by Wall St. Rank reported a position in BioLineRX (BLRX) for Q1 2020, worth a combined $3.69M — down 40% from $6.14M a quarter earlier.

Buyers outnumbered sellers: 3 funds opened new BLRX positions and 1 closed out — a net gain of 2 holders — while 2 added to existing stakes and 2 trimmed.

The largest buyer was Morgan Stanley, adding an estimated $174K. The largest seller was Senvest Management, cutting an estimated $208K.

  • 13 institutional investors held BioLineRX (BLRX) as of Q1 2020, up from 12 in Q4 2019.
  • Funds reported $3.69M of BioLineRX stock for Q1 2020, down 40% quarter-over-quarter.
  • 3 funds opened new BioLineRX positions in Q1 2020 and 1 closed out, a net change of +2 holders.
  • The largest BioLineRX buyer in Q1 2020 was Morgan Stanley, an estimated $174K added.
  • The largest BioLineRX seller in Q1 2020 was Senvest Management, an estimated $208K sold.

Based on aggregated 13F filings for Q1 2020.